The global multiple myeloma treatment market is expected to rise steadily at a CAGR of 11.0% during the forecast period from 2018–2023.
Multiple myeloma is a cancer of plasma cells. Plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is made up of several types of cells which includes T cells and B cells that work together to fight against infections and other diseases. Lymphocytes are one of the important types of white blood cells (WBCs) in the immune system. Different types of lymphocytes are present in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream.
The global multiple myeloma market is anticipated to grow by an increase in aging population, increase in healthcare expenditure, and increasing use of novel cancer drugs in the market, whereas increasing prevalence of disease along with growing elderly population is the prime factor to drive the growth of this market during the forecast period. It has also been observed that the upcoming drug pipeline of multiple myeloma is promising. Other factors such as biological drugs and stem cell therapies are expected to drive the market in the future. The key players in the market are accelerating the research and development activities for multiple myeloma treatment. In 2018, drugs therapy is expected to be the largest market due to key driving factors such as rising demand for non-invasive treatments, and incessant development in research and development activities.
Despite the drivers, factors such as the high cost of treatment and limited target patient population may hinder the growth of the market.
Key players:
Some of the key players in the global multiple myeloma treatment market are Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals, Amgen, Inc., Genzyme Corporation, Juno Therapeutics, Johnson & Johnson, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AbbVie Inc., Novartis AG, Innate Pharma SA, and Celldex Therapeutics, Inc., Onyx Pharmaceuticals, Pfizer, Takeda Pharmaceuticals.
Market Segmentation:
Global multiple myeloma treatment is further segmented into treatment types and end-users. Based on treatment types the market is segmented into chemotherapy, corticosteroids, interferon, stem cell transplant, and radiation therapy. Chemotherapy is further sub-segmented into bendamustine (treanda), cyclophosphamide (Cytoxan), doxorubicin (adriamycin), etoposide (vp-16), liposomal doxorubicin (Doxil), melphalan (Alkeran, evomela), vincristine (Oncovin). On the basis of end-user global multiple myeloma treatment market is further segmented into hospitals, clinics, rehabilitative center treatment, independent pharmacies, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The multiple myeloma treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of multiple myeloma treatment market.
Segmentation
Global Multiple Myeloma Treatment Market, by Treatment
- Chemotherapy
- Bendamustine (Treanda)
- Cyclophosphamide (Cytoxan)
- Doxorubicin (Adriamycin)
- Etoposide
- Liposomal doxorubicin (Doxil)
- Melphalan (Alkeran, Evomela)
- Vincristine (Oncovin)
- Corticosteroids
- Interferon
- Stem Cell Transplant
- Radiation Therapy
Global Multiple Myeloma Treatment Market, by End User
- Hospitals
- Clinics
- Independent pharmacies
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization